(5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile manufacturers
- ZINC05007751
-
- $51.00
-
2026-07-27
- CAS:591239-68-8
- Purity: 99.75%
- Supply Ability: 10g
|
| | (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile Basic information |
| Product Name: | (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile | | Synonyms: | (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile;NEK6 inibitor 8;ZINC05007751;3-Pyridinecarbonitrile, 1,2,5,6-tetrahydro-4-methyl-2,6-dioxo-5-[(5-phenyl-2-furanyl)methylene]-;NEK6 inhibitor 8;HCT-15,NCI-H1299,PEO1,ovarian,Inhibitor,ZINC 05007751,inhibit,cells,ZINC05007751,NEK6,antiproliferative,ZINC-05007751;4-Methyl-2,6-dioxo-5-((5-phenylfuran-2-yl)methylene)-1,2,5,6-tetrahydropyridine-3-carbonitrile;ZINC05007751, 10 mM in DMSO | | CAS: | 591239-68-8 | | MF: | C18H12N2O3 | | MW: | 304.3 | | EINECS: | | | Product Categories: | | | Mol File: | 591239-68-8.mol | ![(5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile Structure](CAS/20180601/GIF/591239-68-8.gif) |
| | (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile Chemical Properties |
| Boiling point | 504.926±50.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.348±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 8.33 mg/mL (27.37 mM; ultrasonic and warming and heat to 60°C) | | form | Solid | | pka | 5.869±0.60(predicted) | | color | Brown to black |
| | (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile Usage And Synthesis |
| Uses | ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9[1]. | | Biological Activity | ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9[1].
ZINC05007751 (6 μM-190 μM; 24 hours) inhibits the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15 with IC50 below 100 μM[1].ZINC05007751 induces perturbation of PEO1 cell cycle[1].ZINC05007751 (ovarian cancer cells PEO1) shows synergism with Cisplatin, resulting in a significant reduction of Cisplatin IC50 from 7.9 to 0.1 μM, with combination ZINC05007751 (44 μM) + Cisplatin (10 μM) exhibiting the greatest synergistic effect[1]. | | IC 50 | NEK6: 3.4 μM (IC50) | | References | [1]. De Donato M, et al. Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6. Sci Rep. 2018;8(1):16047. Published 2018 Oct 30. |
| | (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile Preparation Products And Raw materials |
|